Jonathan W Mink

List of Publications by Year
in descending order

151	12,615	76326	26613
papers	citations	40 h-index	107 g-index

239	239	239	10816
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS. Progress in Neurobiology, 1996, 50, 381-425.	5.7	2,258
2	Phenomenology and classification of dystonia: A consensus update. Movement Disorders, 2013, 28, 863-873.	3.9	1,754
3	DEEP BRAIN STIMULATION. Annual Review of Neuroscience, 2006, 29, 229-257.	10.7	820
4	Classification and Definition of Disorders Causing Hypertonia in Childhood. Pediatrics, 2003, 111, e89-e97.	2.1	641
5	The Basal Ganglia and Involuntary Movements. Archives of Neurology, 2003, 60, 1365.	4.5	487
6	Recent advances in Tourette syndrome research. Trends in Neurosciences, 2006, 29, 175-182.	8.6	436
7	Definition and classification of hyperkinetic movements in childhood. Movement Disorders, 2010, 25, 1538-1549.	3.9	374
8	Basal ganglia dysfunction in Touretteâ€™s syndrome: a new hypothesis. Pediatric Neurology, 2001, 25, 190-198.	2.1	331
9	Basal ganglia intrinsic circuits and their role in behavior. Current Opinion in Neurobiology, 1993, 3, 950-957.	4.2	282
10	Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx, 2006, 3, 192-206.	6.0	273
11	Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia due to Cerebral Palsy. Journal of Child Neurology, 2007, 22, 530-537.	1.4	243
12	Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Movement Disorders, 2006, 21, 1831-1838.	3.9	238
13	Tourette syndrome deep brain stimulation: A review and updated recommendations. Movement Disorders, 2015, 30, 448-471.	3.9	236
14	Definition and Classification of Negative Motor Signs in Childhood. Pediatrics, 2006, 118, 2159-2167.	2.1	226
15	NCL diseases â€” clinical perspectives. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1801-1806.	3.8	194
16	Conversion disorder and mass psychogenic illness in child neurology. Annals of the New York Academy of Sciences, 2013, 1304, 40-44.	3.8	165
17	Neurobehavioral Features and Natural History of Juvenile Neuronal Ceroid Lipofuscinosis (Batten) Tj ETQq1 1 0.784314 rgBT /Overloc	1.4	160
18	Clinical Trials in Rare Disease. Journal of Child Neurology, 2013, 28, 1142-1150.	1.4	155

#	Article	IF	Citations
19	Dystonia rating scales: Critique and recommendations. Movement Disorders, 2013, 28, 874-883.	3.9	150
20	Advances in understanding and treatment of Tourette syndrome. Nature Reviews Neurology, 2011, 7, 667-676.	10.1	145
21	Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. Developmental Medicine and Child Neurology, 2010, 52, e83-7.	2.1	130
22	Classification and Natural History of the Neuronal Ceroid Lipofuscinoses. Journal of Child Neurology, 2013, 28, 1101-1105.	1.4	117
23	Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. Advances in Neurology, 2006, 99, 89-98.	0.8	112
24	Moving from PANDAS to CANS. Journal of Pediatrics, 2012, 160, 725-731.	1.8	101
25	A Trial of Scheduled Deep Brain Stimulation for Tourette Syndrome. JAMA Neurology, 2013, 70, 85.	9.0	96
26	Posterior vermal split syndrome. Annals of Neurology, 1998, 44, 601-610.	5.3	91
27	A National Profile of Tourette Syndrome, 2011â€“2012. Journal of Developmental and Behavioral Pediatrics, 2014, 35, 317-322.	1.1	90
28	Masturbation in Infancy and Early Childhood Presenting as a Movement Disorder: 12 Cases and a Review of the Literature. Pediatrics, 2005, 116, 1427-1432.	2.1	87
29	Current controversies on the role of behavior therapy in Tourette syndrome. Movement Disorders, 2013, 28, 1179-1183.	3.9	87
30	Advances in management of movement disorders in children. Lancet Neurology, The, 2016, 15, 719-735.	10.2	84
31	Hereditary Spastic Paraplegia. , 2022, , 415-440.		82
32	Management Strategies for CLN2 Disease. Pediatric Neurology, 2017, 69, 102-112.	2.1	80
33	ATP1A3 mutations in infants: a new rapidâ€onset dystoniaâ€“Parkinsonism phenotype characterized by motor delay and ataxia. Developmental Medicine and Child Neurology, 2012, 54, 1065-1067.	2.1	78
34	Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Developmental Medicine and Child Neurology, 2018, 60, 356-366.	2.1	72
35	Dysfunction of dopaminergic pathways in dystonia. Advances in Neurology, 2004, 94, 163-70.	0.8	65
36	Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates. Annals of Neurology, 2014, 76, 393-402.	5.3	58

#	Article	IF	Citations
37	Special concerns in defining, studying, and treating dystonia in children. Movement Disorders, 2013, 28, 921-925.	3.9	55
38	Psychogenic movement disorders in children. Pediatric Neurology, 2004, 30, 1-6.	2.1	54
39	Females experience a more severe disease course in batten disease. Journal of Inherited Metabolic Disease, 2012, 35, 549-555.	3.6	54
40	Response to levodopa challenge in Tourette syndrome. Movement Disorders, 2000, 15, 1194-1198.	3.9	52
41	Impaired Reaching and Grasping After Focal Inactivation of Globus Pallidus Pars Interna in the Monkey. Journal of Neurophysiology, 1999, 82, 2049-2060.	1.8	50
42	Microinfusion of antineuronal antibodies into rodent striatum: Failure to differentiate between elevated and low titers. Journal of Neuroimmunology, 2005, 163, 8-14.	2.3	44
43	SUICIDAL THOUGHTS AND BEHAVIORS IN CHILDREN AND ADOLESCENTS WITH CHRONIC TIC DISORDERS. Depression and Anxiety, 2015, 32, 744-753.	4.1	44
44	A Pediatric Neurology Perspective on Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection and Pediatric Acute-Onset Neuropsychiatric Syndrome. Journal of Pediatrics, 2018, 199, 243-251.	1.8	42
45	Thalamic stimulation for primary writing tremor. Journal of Neurology, 2001, 248, 380-382.	3.6	41
46	Activity of basal forebrain neurons in the rat during motivated behaviors. Behavioural Brain Research, 1983, 8, 85-108.	2.2	39
47	Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 438-442.	1.8	37
48	Motor benefit from levodopa in spastic quadriplegic cerebral palsy. Annals of Neurology, 2000, 47, 662-665.	5.3	35
49	Batten Disease. Journal of Child Neurology, 2013, 28, 1074-1100.	1.4	34
50	Thimerosal Exposure in Early Life and Neuropsychological Outcomes 7â€“10 Years Later. Journal of Pediatric Psychology, 2012, 37, 106-118.	2.1	33
51	Neuropsychological Symptoms of Juvenile-Onset Batten Disease: Experiences From 2 Studies. Journal of Child Neurology, 2007, 22, 621-627.	1.4	31
52	Phenotypes, genotypes, and the management of paroxysmal movement disorders. Developmental Medicine and Child Neurology, 2018, 60, 559-565.	2.1	31
53	Progressive myoclonus in a child with a deep cerebellar mass. Neurology, 2003, 61, 829-831.	1.1	29
54	Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Molecular Genetics and Metabolism, 2016, 118, 65-69.	1.1	28

#	Article	IF	Citations
55	Report of a workshop on research gaps in the treatment of cerebral palsy. Neurology, 2016, 87, 1293-1298.	1.1	28
56	Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.5	27
57	Basal ganglia mechanisms in action selection, plasticity, and dystonia. European Journal of Paediatric Neurology, 2018, 22, 225-229.	1.6	26
58	Children with Tourette Syndrome in the United States: Parent-Reported Diagnosis, Co-Occurring Disorders, Severity, and Influence of Activities on Tics. Journal of Developmental and Behavioral Pediatrics, 2019, 40, 407-414.	1.1	25
59	Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease). Developmental Medicine and Child Neurology, 2010, 52, 637-643.	2.1	24
60	Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis. Developmental Medicine and Child Neurology, 2015, 57, 366-371.	2.1	24
61	Regional, not global, functional connectivity contributes to isolated focal dystonia. Neurology, 2020, 95, e2246-e2258.	1.1	23
62	Methodology of clinical research in rare diseases: Development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates. Contemporary Clinical Trials, 2013, 35, 48-54.	1.8	22
63	Progress in research on Tourette syndrome. Journal of Obsessive-Compulsive and Related Disorders, 2014, 3, 359-362.	1.5	22
64	<scp>GNAO</scp>1â€Associated Movement Disorder. Movement Disorders Clinical Practice, 2016, 3, 615-617.	1.5	22
65	Preferential relation of pallidal neurons to ballistic movements. Brain Research, 1987, 417, 393-398.	2.2	21
66	Remote Assessment of Cognitive Function in Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease). Journal of Child Neurology, 2016, 31, 481-487.	1.4	21
67	Bilateral deep brain stimulation for treatment of medically refractory paroxysmal nonkinesigenic dyskinesia. Journal of Neurosurgery, 2010, 112, 847-850.	1.6	20
68	Tic Disorders are Associated With Lower Child and Parent Quality of Life and Worse Family Functioning. Pediatric Neurology, 2020, 105, 48-54.	2.1	19
69	A human model of Batten disease shows role of CLN3 in phagocytosis at the photoreceptorâ€“RPE interface. Communications Biology, 2021, 4, 161.	4.4	19
70	Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Developmental Medicine and Child Neurology, 2006, 48, 259-264.	2.1	18
71	Treatment of Paroxysmal Dyskinesias in Children. Current Treatment Options in Neurology, 2015, 17, 350.	1.8	18
72	Pilot Testing Behavior Therapy for Chronic Tic Disorders in Neurology and Developmental Pediatrics Clinics. Journal of Child Neurology, 2016, 31, 444-450.	1.4	18

#	Article	IF	Citations
73	The CLN3 Disease Staging System. Neurology, 2020, 94, e2436-e2440.	1.1	18
74	Immune defenses of Xenopus laevis against Batrachochytrium dendrobatidis. Frontiers in Bioscience - Elite, 2009, 1, 68.	1.8	17
75	Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet Journal of Rare Diseases, 2021, 16, 185.	2.7	17
76	Spatial Reorganization of Putaminal Dopamine D2-Like Receptors in Cranial and Hand Dystonia. PLoS ONE, 2014, 9, e88121.	2.5	17
77	Treatment of Chorea in Childhood. Pediatric Neurology, 2020, 102, 10-19.	2.1	16
78	The Rise of Functional Tic-Like Behaviors: What Do the COVID-19 Pandemic and Social Media Have to Do With It? A Narrative Review. Frontiers in Pediatrics, 0, 10, .	1.9	15
79	Dopa-responsive dystonia in children. Current Treatment Options in Neurology, 2003, 5, 279-282.	1.8	14
80	Neurophysiological biomarkers to optimize deep brain stimulation in movement disorders. Neurodegenerative Disease Management, 2021, 11, 315-328.	2.2	14
81	Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials. Basal Ganglia, 2016, 6, 173-181.	0.3	13
82	Academic, Interpersonal, Recreational, and Family Impairment in Children with Tourette Syndrome and Attention-Deficit/Hyperactivity Disorder. Child Psychiatry and Human Development, 2021, , 1.	1.9	13
83	Paroxysmal dyskinesias. Current Opinion in Pediatrics, 2007, 19, 652-656.	2.0	12
84	Quantitative, clinically relevant acoustic measurements of focal embouchure dystonia. Movement Disorders, 2018, 33, 449-458.	3.9	12
85	Movement disorders in children with congenital Zika virus syndrome. Brain and Development, 2020, 42, 720-729.	1.1	12
86	New treatments for tic disorders. Current Treatment Options in Neurology, 2006, 8, 465-473.	1.8	11
87	Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease;) Tj ETQq1 1 0.784314 rgBT /Overlock	3.6	11
88	Acute Postinfectious Movement and Psychiatric Disorders in Children and Adolescents. Journal of Child Neurology, 2011, 26, 214-217.	1.4	11
89	Experience, knowledge, and opinions about childhood genetic testing in Batten disease. Molecular Genetics and Metabolism, 2014, 111, 197-202.	1.1	11
90	Movement Disorders II: Chorea, Dystonia, Myoclonus, and Tremor. Pediatrics in Review, 2010, 31, 287-295.	0.4	10

#	Article	IF	Citations
91	Management of CLN1 Disease: International Clinical Consensus. Pediatric Neurology, 2021, 120, 38-51.	2.1	10
92	Batten disease: an expert update on agents in preclinical and clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 1317-1322.	4.1	9
93	Anxiety Symptoms Differ in Youth With and Without Tic Disorders. Child Psychiatry and Human Development, 2021, 52, 301-310.	1.9	9
94	Movement Disorders in Children. Pediatrics in Review, 2003, 24, 39-51.	0.4	8
95	The Basal Ganglia. , 2013, , 653-676.		7
96	Correcting honest pervasive errors in the scientific literature. Neurology, 2017, 89, 11-13.	1.1	7
97	Treatment use among children with Tourette syndrome living in the United States, 2014. Psychiatry Research, 2020, 293, 113400.	3.3	6
98	Faulty brakes?. Neurology, 2011, 76, 592-593.	1.1	5
99	The impact of development on the interpretation of movement disorders rating scales. Developmental Medicine and Child Neurology, 2014, 56, 511-512.	2.1	5
100	â€œComplexâ€•dystonia is not a category in the new 2013 consensus classification. Movement Disorders, 2016, 31, 1758-1759.	3.9	5
101	Intravenous Immunoglobulin Is Not an Effective Treatment for Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 837-838.	0.5	5
102	Movement Disorders I: Tics and Stereotypies. Pediatrics in Review, 2010, 31, 223-233.	0.4	5
103	Letters to the Editor. Movement Disorders, 1998, 13, 980-982.	3.9	4
104	Enzyme Replacement in Neuronal Storage Disorders in the Pediatric Population. Current Treatment Options in Neurology, 2013, 15, 634-651.	1.8	4
105	Developing a New Set of ACGME Milestones for Child Neurology Residency. Pediatric Neurology, 2021, 114, 47-52.	2.1	4
106	Risk Behaviors in Youth With and Without Tourette Syndrome. Pediatric Neurology, 2022, 126, 20-25.	2.1	4
107	Natural history data for childhood neurodegenerative disease. The Lancet Child and Adolescent Health, 2018, 2, 547-548.	5.6	3
108	A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an ultra-rare lysosomal storage disorder. Clinical Trials, 2019, 16, 555-560.	1.6	3

#	Article	IF	Citations
109	The President, Past President, Executive Director, and the Board of the Child Neurology Society Denounce Racism and Inequality. Annals of Neurology, 2020, 88, 209-210.	5.3	3
110	A diagnostic confidence scheme for <scp>CLN3</scp> disease. Journal of Inherited Metabolic Disease, 2021, 44, 1453-1462.	3.6	3
111	The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample. European Journal of Paediatric Neurology, 2022, 38, 62-65.	1.6	3
112	Reply: Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Movement Disorders, 2007, 22, 1367-1368.	3.9	2
113	Metabolic Encephalopathies. , 2012, , 153-161.		2
114	Paroxysmal Dyskinesias. Journal of Pediatric Neurology, 2015, 13, 225-230.	0.2	2
115	Management of movement disorders in children â€“ Authorsâ€™ reply. Lancet Neurology, The, 2016, 15, 1302-1303.	10.2	2
116	Temporal and kinematic consistency predict sequence awareness. Experimental Brain Research, 2016, 234, 3025-3036.	1.5	2
117	Screening tools for tic disorders-Focus on development or implementation?. Movement Disorders, 2017, 32, 946-946.	3.9	2
118	Basal Ganglia Anatomy, Biochemistry, and Physiology. , 2010, , 2-8.		1
119	Neurologic Complications of Cardiac Surgery. , 2012, , 174-181.		1
120	Paroxysmal dyskinesias. Journal of Pediatric Neurology, 2015, 08, 065-067.	0.2	1
121	Alterations in vestibular function in individuals with cervical dystonia and the effects of botulinum toxin treatment. Basal Ganglia, 2018, 13, 1-6.	0.3	1
122	Motor sequence awareness is impaired in dystonia despite normal performance. Annals of Neurology, 2018, 83, 52-60.	5.3	1
123	Basal Ganglia Anatomy, Biochemistry, and Physiology. , 2016, , 3-12.		1
124	Tics and Tourette Syndrome. , 2022, , 99-140.		1
125	Pediatric Movement Disorders. , 2008, , 469-476.		0
126	Tics and Tourette Syndrome. , 2010, , 40-55.		0

#	Article	IF	Citations
127	Application of MR Diffusion, CT Angiography and Perfusion Imaging in Stroke Neurocritical Care. , 2012, , 205-213.		0
128	Classification of Movement Disorders. , 2016, , 27-35.		0
129	Functional (Psychogenic) Movement Disorders. , 2016, , 515-524.		0
130	Reply. Journal of Pediatrics, 2019, 204, 326-327.	1.8	0
131	Reply. Journal of Pediatrics, 2019, 204, 324-325.	1.8	0
132	Basal Ganglia Circuits and Thalamocortical Outputs. Neurological Disease and Therapy, 2004, , 253-272.	0.0	0
133	Functional Anatomy of the Basal Ganglia. Medical Psychiatry, 2006, , 45-56.	0.2	0
134	Functional anatomy of the basal ganglia. , 2012, , 53-64.		0
135	Diagnostic Evaluation of Children With Movement Disorders. , 2022, , 43-67.		0
136	Tremor. , 2022, , 305-331.		0
137	Ataxia. , 2022, , 333-394.		0
138	Drug-Induced Movement Disorders in Children. , 2022, , 637-666.		0
139	Basal Ganglia Anatomy, Biochemistry, and Physiology. , 2022, , 3-13.		0
140	Movement Disorders in Sleep. , 2022, , 561-589.		0
141	Movement Disorders in Autoimmune Diseases. , 2022, , 535-560.		0
142	Functional Movement Disorders. , 2022, , 667-679.		0
143	Motor Assessments. , 2022, , 69-81.		0
144	Motor Stereotypies. , 2022, , 141-164.		0

#	Article	IF	Citations
145	Chorea, Athetosis, and Ballism. , 2022, , 183-228.		0
146	Classification of Movement Disorders. , 2022, , 33-42.		0
147	Transient and Developmental Movement Disorders. , 2022, , 85-96.		0
148	Movement Disorders and Neuropsychiatric Conditions. , 2022, , 619-636.		0
149	Metabolic Disorders With Associated Movement Abnormalities. , 2022, , 443-533.		0
150	Cerebellar Anatomy, Biochemistry, Physiology, and Plasticity. , 2022, , 15-32.		0
151	Myoclonus. , 2022, , 263-303.		0